Cosentyx secukinumab: Additional Phase IIIb data

Additional data from the 52-week, double-blind, international Phase IIIb CLEAR trial in 679 patients with moderate to severe plaque psoriasis showed that Cosentyx led to a PASI 90 response rate at wee...